These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 4043164)

  • 1. Association of N-acetyltransferase polymorphism and environmental factors with bladder carcinogenesis. Study in a north German population.
    Hanssen HP; Agarwal DP; Goedde HW; Bucher H; Huland H; Brachmann W; Ovenbeck R
    Eur Urol; 1985; 11(4):263-6. PubMed ID: 4043164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark.
    Lower GM; Nilsson T; Nelson CE; Wolf H; Gamsky TE; Bryan GT
    Environ Health Perspect; 1979 Apr; 29():71-9. PubMed ID: 510245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupational history and genetic N-acetyltransferase polymorphism in urothelial cancer patients of Leverkusen, Germany.
    Golka K; Prior V; Blaszkewicz M; Cascorbi I; Schöps W; Kierfeld G; Roots I; Bolt HM
    Scand J Work Environ Health; 1996 Oct; 22(5):332-8. PubMed ID: 8923605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of N-acetyltransferase phenotype in human susceptibility to bladder carcinogenic arylamines.
    Wolf H; Lower GM; Bryan GT
    Scand J Urol Nephrol; 1980; 14(2):161-5. PubMed ID: 7209420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More on adducts and addicts. Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer.
    Coggon D
    Hum Exp Toxicol; 1995 Jun; 14(6):538-9. PubMed ID: 8519531
    [No Abstract]   [Full Text] [Related]  

  • 6. Association of NAT1 and NAT2 polymorphisms to urinary bladder cancer: significantly reduced risk in subjects with NAT1*10.
    Cascorbi I; Roots I; Brockmöller J
    Cancer Res; 2001 Jul; 61(13):5051-6. PubMed ID: 11431340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer.
    Cartwright RA; Glashan RW; Rogers HJ; Ahmad RA; Barham-Hall D; Higgins E; Kahn MA
    Lancet; 1982 Oct; 2(8303):842-5. PubMed ID: 6126711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Acetyltransferase phenotype of patients with bladder cancer.
    Karakaya AE; Cok I; Sardas S; Gögüs O; Sardas OS
    Hum Toxicol; 1986 Sep; 5(5):333-5. PubMed ID: 3770769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. N-acetyltransferase 2 phenotype in painters with bladder cancer and controls.
    Golka K; Weistenhofer W; Jedrusik P; Geller F; Blaszkewicz M; Bolt HM
    Ann Acad Med Singap; 2001 Sep; 30(5):464-7. PubMed ID: 11603126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Acetyltransferase phenotypes in the urinary bladder carcinogenesis of a low-risk population.
    Mommsen S; Barfod NM; Aagaard J
    Carcinogenesis; 1985 Feb; 6(2):199-201. PubMed ID: 3971485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Occupational and non-occupational risk factors in bladder cancer patients in an industrialized area located in former East-Germany].
    Golka K; Seidel T; Dietrich H; Roth G; Rötzel C; Thier R; Geller F; Reckwitz T; Schulze H
    Aktuelle Urol; 2005 Sep; 36(5):417-22. PubMed ID: 16163604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical relevance of acetylator phenotyping in 196 urothelial tumor patients].
    Schöps W; Prior V; Golka K; Blaszkewicz M; Cascorbi I; Roots I; Bolt HM; Kierfeld G
    Urologe A; 1997 Jan; 36(1):64-7. PubMed ID: 9123684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated pulmonary disorders.
    Hirvonen A; Saarikoski ST; Linnainmaa K; Koskinen K; Husgafvel-Pursiainen K; Mattson K; Vainio H
    J Natl Cancer Inst; 1996 Dec; 88(24):1853-6. PubMed ID: 8961976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism and cancer susceptibility: evidence concerning acetyltransferases and cancer of the urinary bladder.
    Hein DW
    Bioessays; 1988 Dec; 9(6):200-4. PubMed ID: 3072000
    [No Abstract]   [Full Text] [Related]  

  • 16. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors.
    Schroeder JC; Conway K; Li Y; Mistry K; Bell DA; Taylor JA
    Cancer Res; 2003 Nov; 63(21):7530-8. PubMed ID: 14612556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyltransferase phenotypes in bladder tumour patients with and without carcinoma in situ in selected site biopsies.
    Mommsen S; Wolf H
    Scand J Urol Nephrol; 1985; 19(3):203-4. PubMed ID: 4070990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Determination of the N-acetyltransferase phenotype in urothelial cancer patients and healthy controls].
    Sone M
    Hinyokika Kiyo; 1986 Aug; 32(8):1085-92. PubMed ID: 3788733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-acetyltransferase 2 phenotype but not NAT1*10 genotype affects aminobiphenyl-hemoglobin adduct levels.
    Probst-Hensch NM; Bell DA; Watson MA; Skipper PL; Tannenbaum SR; Chan KK; Ross RK; Yu MC
    Cancer Epidemiol Biomarkers Prev; 2000 Jun; 9(6):619-23. PubMed ID: 10868698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-acetyltransferase 2 gene polymorphism as a biomarker for susceptibility to bladder cancer in Bangladeshi population.
    Hosen MB; Islam J; Salam MA; Islam MF; Hawlader MZ; Kabir Y
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):78-84. PubMed ID: 25376209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.